DE19963538A1 - Verwendung eines Enzyms zur Verbesserung der Geweberesorption von Arzneimitteln - Google Patents

Verwendung eines Enzyms zur Verbesserung der Geweberesorption von Arzneimitteln

Info

Publication number: DE19963538A1
Authority: DE; Germany
Prior art keywords: use according; fragment; microbial; hyaluronate lyase; active ingredient
Prior art date: 1999-12-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

DE1999163538

Other languages

German (de)

English (en)

Inventor

Joerg-Hermann Ozegowski

Peter-Juergen Mueller

Albert Haertl

Manfred Kietzmann

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Friedrich Schiller Universtaet Jena FSU

Leibniz Institut fuer Naturstoff Forschung und Infektionsbiol eVi

Original Assignee

Friedrich Schiller Universtaet Jena FSU

Leibniz Institut fuer Naturstoff Forschung und Infektionsbiol eVi

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-22

Filing date

1999-12-22

Publication date

2001-07-05

1999-12-22 Application filed by Friedrich Schiller Universtaet Jena FSU, Leibniz Institut fuer Naturstoff Forschung und Infektionsbiol eVi filed Critical Friedrich Schiller Universtaet Jena FSU

1999-12-22 Priority to DE1999163538 priority Critical patent/DE19963538A1/de

2000-12-19 Priority to AU30146/01A priority patent/AU3014601A/en

2000-12-19 Priority to PCT/EP2000/012970 priority patent/WO2001045743A2/fr

2001-07-05 Publication of DE19963538A1 publication Critical patent/DE19963538A1/de

Status Withdrawn legal-status Critical Current

Links

239000003814 drug Substances 0.000 title claims abstract description 28
102000004190 Enzymes Human genes 0.000 title claims description 26
108090000790 Enzymes Proteins 0.000 title claims description 26
238000010521 absorption reaction Methods 0.000 title claims description 26
229940079593 drug Drugs 0.000 title claims description 22
108010003272 Hyaluronate lyase Proteins 0.000 claims abstract description 53
239000012634 fragment Substances 0.000 claims abstract description 22
230000000813 microbial effect Effects 0.000 claims abstract description 18
241001465754 Metazoa Species 0.000 claims abstract description 14
239000013543 active substance Substances 0.000 claims abstract description 3
239000004480 active ingredient Substances 0.000 claims description 22
238000002347 injection Methods 0.000 claims description 20
239000007924 injection Substances 0.000 claims description 20
239000000243 solution Substances 0.000 claims description 12
244000005700 microbiome Species 0.000 claims description 10
230000010412 perfusion Effects 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 9
229940035674 anesthetics Drugs 0.000 claims description 8
230000003327 cancerostatic effect Effects 0.000 claims description 8
239000003193 general anesthetic agent Substances 0.000 claims description 8
238000000855 fermentation Methods 0.000 claims description 7
230000004151 fermentation Effects 0.000 claims description 7
238000000034 method Methods 0.000 claims description 5
241000193985 Streptococcus agalactiae Species 0.000 claims description 4
241000264435 Streptococcus dysgalactiae subsp. equisimilis Species 0.000 claims description 4
239000000706 filtrate Substances 0.000 claims description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
241000194017 Streptococcus Species 0.000 claims description 3
239000008103 glucose Substances 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
238000000108 ultra-filtration Methods 0.000 claims description 3
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
229940035676 analgesics Drugs 0.000 claims description 2
239000000730 antalgic agent Substances 0.000 claims description 2
AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 claims description 2
230000007717 exclusion Effects 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
238000001471 micro-filtration Methods 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
239000011148 porous material Substances 0.000 claims description 2
108010009004 proteose-peptone Proteins 0.000 claims description 2
239000012141 concentrate Substances 0.000 claims 1
239000001963 growth medium Substances 0.000 claims 1
239000012528 membrane Substances 0.000 claims 1
229940124531 pharmaceutical excipient Drugs 0.000 claims 1
102000001974 Hyaluronidases Human genes 0.000 description 27
210000001519 tissue Anatomy 0.000 description 27
229940088598 enzyme Drugs 0.000 description 21
229960002773 hyaluronidase Drugs 0.000 description 19
206010028980 Neoplasm Diseases 0.000 description 18
108091005804 Peptidases Proteins 0.000 description 18
239000004365 Protease Substances 0.000 description 17
230000000694 effects Effects 0.000 description 17
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 16
239000000203 mixture Substances 0.000 description 16
238000009472 formulation Methods 0.000 description 13
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 12
229920002674 hyaluronan Polymers 0.000 description 11
229960003160 hyaluronic acid Drugs 0.000 description 10
230000002381 testicular Effects 0.000 description 10
238000004140 cleaning Methods 0.000 description 9
108050009363 Hyaluronidases Proteins 0.000 description 8
229920002683 Glycosaminoglycan Polymers 0.000 description 7
108010025076 Holoenzymes Proteins 0.000 description 5
230000009471 action Effects 0.000 description 5
235000002639 sodium chloride Nutrition 0.000 description 5
239000007787 solid Substances 0.000 description 5
238000007920 subcutaneous administration Methods 0.000 description 5
241000283690 Bos taurus Species 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
230000001133 acceleration Effects 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000029087 digestion Effects 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000011282 treatment Methods 0.000 description 4
108010088751 Albumins Proteins 0.000 description 3
102000009027 Albumins Human genes 0.000 description 3
206010002091 Anaesthesia Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000037005 anaesthesia Effects 0.000 description 3
-1 aromatic amino acids Chemical class 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
230000035515 penetration Effects 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
108010006035 Metalloproteases Proteins 0.000 description 2
102000005741 Metalloproteases Human genes 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
108010058846 Ovalbumin Proteins 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
239000012614 Q-Sepharose Substances 0.000 description 2
241000187391 Streptomyces hygroscopicus Species 0.000 description 2
239000000654 additive Substances 0.000 description 2
150000001413 amino acids Chemical group 0.000 description 2
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
229910052921 ammonium sulfate Inorganic materials 0.000 description 2
235000011130 ammonium sulphate Nutrition 0.000 description 2
230000003444 anaesthetic effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
229940044683 chemotherapy drug Drugs 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000009826 distribution Methods 0.000 description 2
210000002744 extracellular matrix Anatomy 0.000 description 2
230000004992 fission Effects 0.000 description 2
239000000499 gel Substances 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
230000003100 immobilizing effect Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
229960003299 ketamine Drugs 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
229940126601 medicinal product Drugs 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
239000008267 milk Substances 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
229940092253 ovalbumin Drugs 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
230000007017 scission Effects 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
RCXKSJDIEWGNFE-UHFFFAOYSA-N 2-(n-aminoanilino)-2-oxoacetic acid Chemical compound OC(=O)C(=O)N(N)C1=CC=CC=C1 RCXKSJDIEWGNFE-UHFFFAOYSA-N 0.000 description 1
241001535291 Analges Species 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
102400000107 C-terminal peptide Human genes 0.000 description 1
108010076119 Caseins Proteins 0.000 description 1
229920002271 DEAE-Sepharose Polymers 0.000 description 1
108010059378 Endopeptidases Proteins 0.000 description 1
102000005593 Endopeptidases Human genes 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
206010021118 Hypotonia Diseases 0.000 description 1
102000004317 Lyases Human genes 0.000 description 1
108090000856 Lyases Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
239000012506 Sephacryl® Substances 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
239000012505 Superdex™ Substances 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
239000003655 absorption accelerator Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
239000003708 ampul Substances 0.000 description 1
238000001949 anaesthesia Methods 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
235000013351 cheese Nutrition 0.000 description 1
230000003034 chemosensitisation Effects 0.000 description 1
239000006114 chemosensitizer Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000012531 culture fluid Substances 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000036576 dermal application Effects 0.000 description 1
238000003795 desorption Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000000058 esterolytic effect Effects 0.000 description 1
230000005284 excitation Effects 0.000 description 1
210000001723 extracellular space Anatomy 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000011049 filling Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
229940099552 hyaluronan Drugs 0.000 description 1
108010023571 hylase Proteins 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000000937 inactivator Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000036640 muscle relaxation Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000004963 pathophysiological condition Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
229940096055 prax Drugs 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000036280 sedation Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000007704 transition Effects 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Botany (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)

DE1999163538 1999-12-22 1999-12-22 Verwendung eines Enzyms zur Verbesserung der Geweberesorption von Arzneimitteln Withdrawn DE19963538A1 (de)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
DE1999163538 DE19963538A1 (de)	1999-12-22	1999-12-22	Verwendung eines Enzyms zur Verbesserung der Geweberesorption von Arzneimitteln
AU30146/01A AU3014601A (en)	1999-12-22	2000-12-19	Use of an enzyme to improve the resorption of medicaments in the tissue
PCT/EP2000/012970 WO2001045743A2 (fr)	1999-12-22	2000-12-19	Utilisation d'une enzyme pour ameliorer la resorption de medicaments dans des tissus

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE1999163538 DE19963538A1 (de)	1999-12-22	1999-12-22	Verwendung eines Enzyms zur Verbesserung der Geweberesorption von Arzneimitteln

Publications (1)

Publication Number	Publication Date
DE19963538A1 true DE19963538A1 (de)	2001-07-05

Family

ID=7934845

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE1999163538 Withdrawn DE19963538A1 (de)	1999-12-22	1999-12-22	Verwendung eines Enzyms zur Verbesserung der Geweberesorption von Arzneimitteln

Country Status (3)

Country	Link
AU (1)	AU3014601A (fr)
DE (1)	DE19963538A1 (fr)
WO (1)	WO2001045743A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10143606A1 (de) *	2001-09-06	2003-03-27	Knoell Hans Forschung Ev	Verfahren zur Konservierung von für die Transplantation vorgesehenen Organen und Geweben
DE10207634B4 (de) *	2002-02-22	2011-03-10	Rainer Burckart	Wasserbecken mit einem innenliegenden, motorengetriebenen Laufband für ein Tier oder einen Menschen

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009037566A2 (fr) *	2007-06-19	2009-03-26	Uvarkina Tamara P	Hyaluronidase et son procédé d'utilisation
DE102007031417A1 (de)	2007-07-04	2009-01-08	Friedrich-Schiller-Universität Jena	Hyaluronatlyase mit erhöhter Wirksamkeit, insbesondere für die Herstellung von pharmazeutischen Formulierungen und Medizinprodukten, sowie deren Verwendung

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19743899A1 (de) *	1997-10-04	1999-04-08	Univ Schiller Jena	Verfahren zur Erhöhung der enzymatischen Aktivität von mikrobieller Hyaluronidase
WO2000038732A1 (fr) *	1998-12-23	2000-07-06	Esparma Gmbh	Hyaluronate lyase utilisee dans des medicaments topiques comme agent facilitant leur penetration
WO2000038647A1 (fr) *	1998-12-23	2000-07-06	Esparma Gmbh	Agents pour proteger la peau, contenant un melange de fragments produit par hydrolyse a partir d'acide hyaluronique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3708575A (en) *	1970-05-13	1973-01-02	Biorex Laboratories Ltd	Method for the treatment of atherosclerosis employing glucuronoglycos-aminoglycan-hyaluronate-lyase
CH628088A5 (en) *	1975-09-17	1982-02-15	Dresden Arzneimittel	Process for obtaining streptococcal metabolic products
HUP0103660A2 (hu) *	1998-12-23	2002-01-28	Id-Pharma Gmbh	Mikróbaeredetű hialuronsavbontó enzimet tartalmazó gyógyászati készítmény

1999
- 1999-12-22 DE DE1999163538 patent/DE19963538A1/de not_active Withdrawn
2000
- 2000-12-19 WO PCT/EP2000/012970 patent/WO2001045743A2/fr not_active Ceased
- 2000-12-19 AU AU30146/01A patent/AU3014601A/en not_active Abandoned

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19743899A1 (de) *	1997-10-04	1999-04-08	Univ Schiller Jena	Verfahren zur Erhöhung der enzymatischen Aktivität von mikrobieller Hyaluronidase
WO2000038732A1 (fr) *	1998-12-23	2000-07-06	Esparma Gmbh	Hyaluronate lyase utilisee dans des medicaments topiques comme agent facilitant leur penetration
WO2000038647A1 (fr) *	1998-12-23	2000-07-06	Esparma Gmbh	Agents pour proteger la peau, contenant un melange de fragments produit par hydrolyse a partir d'acide hyaluronique

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
92328531 DN (=AN) *
94171875 DN (=AN) *
Datenbank MEDLINE: 95056779 DN (=AN) *
Datenbank TOXLIT, 1966:2050 AN *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10143606A1 (de) *	2001-09-06	2003-03-27	Knoell Hans Forschung Ev	Verfahren zur Konservierung von für die Transplantation vorgesehenen Organen und Geweben
DE10207634B4 (de) *	2002-02-22	2011-03-10	Rainer Burckart	Wasserbecken mit einem innenliegenden, motorengetriebenen Laufband für ein Tier oder einen Menschen

Also Published As

Publication number	Publication date
WO2001045743A2 (fr)	2001-06-28
AU3014601A (en)	2001-07-03
WO2001045743A3 (fr)	2002-03-14

Publication	Publication Date	Title
DE60128899T2 (de)	2008-02-21	Verwendung eines botulinumtoxins zur herstellung eines arzneimittels zur peripheren behandlung von schmerzen, die nicht mit muskelspasmen oder kopfschmerzen in verbindung stehen
DE60007001T2 (de)	2004-09-30	Neurotoxine zur behandlung von pankreatischen krankheiten
DE60125986T2 (de)	2007-10-18	Pharmazeutische Zusammensetzungen mit Botulinum Toxin
DE3833319C2 (fr)	1992-06-11
DE69433133T2 (de)	2004-04-01	Lösliches thrombomodulin enthaltende zubereitung
DE69715414T2 (de)	2003-05-15	Stabilisierte pharmazeutische zusammensetzung von bdnf
DE69414904T2 (de)	1999-05-12	Silikat-Polymer enthaltende pharmazeutische Zusammensetzungen
EP0619737A1 (fr)	1994-10-19	Composition pharmaceutique pour le traitement de plaies, cicatrices et cheloides
JP2021520373A (ja)	2021-08-19	Ｃｇｒｐを阻害する際に使用するための神経毒素
EP0430200A1 (fr)	1991-06-05	Médicament pour application s.c. ou i.m. contenant des polypeptides
CH616942A5 (en)	1980-04-30	Method for suppressing the immunogenic action of a biocatalyst.
DE10035156A1 (de)	2002-02-07	Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
DE19510551A1 (de)	1995-09-28	Orale Insulinpräparate und ihre Herstellung
EP1244462B1 (fr)	2004-09-29	Preparation pharmaceutique a base de venin d'araignee, sa preparation et son utilisation pour traiter des affections tumorales
RU2303979C2 (ru)	2007-08-10	Способ получения препарата "янтарный биостимулятор" для повышения резистентности организма животных
DE19963538A1 (de)	2001-07-05	Verwendung eines Enzyms zur Verbesserung der Geweberesorption von Arzneimitteln
EP1299457A1 (fr)	2003-04-09	Hemoglobines mammaliennes compatibles avec du plasma sanguin, reticulees, et conjuguees a des oxydes de polyalkylene, servant de porteurs d'oxygene medicaux artificiels, et fabrication et utilisation de celles-ci
EP2076243B1 (fr)	2014-10-01	Formulation liquide du g-csf
EP1056839A1 (fr)	2000-12-06	Formulation pharmaceutique contenant un enzyme decomposant l'acide hyaluronique et d'origine microbienne
DE69431430T2 (de)	2003-05-22	Faktor XIII zur Behandlung von Hautwunden
US20210338784A1 (en)	2021-11-04	Botulinum Toxin Pharmaceutical Composition Comprising Tannic Acid
EP2155335B1 (fr)	2012-08-01	Composition pharmaceutique, utilisation de la composition pharmaceutique pour le traitement d'une tumeur du cerveau, procédé de fabrication de cette composition et kit contenant la composition pharmaceutique
DE19609261C2 (de)	2000-02-24	Arzneimittel zur Vorbeugung gegen und Behandlung der durch Chemotherapie von Tumorerkrankungen bedingten Myelosuppression
RU2278677C2 (ru)	2006-06-27	Средство для стимулирования эритропоэза и устранения дефицита железа
AT408946B (de)	2002-04-25	Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation

Legal Events

Date	Code	Title	Description
2001-07-05	OM8	Search report available as to paragraph 43 lit. 1 sentence 1 patent law
2002-11-07	8139	Disposal/non-payment of the annual fee

DE19963538A1 - Verwendung eines Enzyms zur Verbesserung der Geweberesorption von Arzneimitteln - Google Patents

Info

Links

Classifications

Landscapes

Priority Applications (3)

Applications Claiming Priority (1)

Publications (1)

Family

ID=7934845

Family Applications (1)

Country Status (3)

Cited By (2)

Families Citing this family (2)

Citations (3)

Family Cites Families (3)

Patent Citations (3)

Non-Patent Citations (4)

Cited By (2)

Also Published As

Similar Documents

Legal Events